



Ref. No.P-66/2024-25/73
February 13, 2025

The Relationship Manager,
Department of Corporate Relations
BSE Limited,
P.J. Towers, Dalal Street
Fort, MUMBAI – 400 001

Dear Sir,

Sub: Integrated Filing (Financial) for the third quarter and nine months ended December 31, 2024

Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024, read with BSE Circular No. 20250102-4 dated January 2, 2025, we are submitting herewith the Integrated Filing (Financial) for the third quarter and nine months ended December 31, 2024.

These are also being made available on the website of the Company at www.kilpest.com.

The Meeting of the Board of Directors held today commenced at 1:30 P.M. and concluded at 3:45 P.M.

You are requested to kindly take the above information on record.

Thanking You,
For 3B BlackBio Dx Limited (Formerly, Kilpest India Limited)

Nikhil Kuber Dubey
Whole Time Director
DIN: 00538049

Encl: As above

QUARTERLY INTEGRATED FILING (FINANCIAL)
A. FINANCIAL RESULTS

3B BLACKBIO DX LTD

(Formerly, Kilpest India Ltd.)

REGD.OFFICE: 7-C, INDUSTRIAL AREA,GOVINDPURA, BHOPAL-462 023

CIN:L24211MP1972PLC001131


Statement of Standalone Unaudited Financial Results for the Quarter and Nine Months ended 31-12-2024

(Rs in lakhs)

S.No.	PARTICULARS	QUARTER ENDED			9 MONTHS ENDED		YEAR ENDED
		31-12-2024 (unaudited)	30-09-2024 (unaudited)	31-12-2023 (unaudited)	31-12-2024 (unaudited)	31-12-2023 (unaudited)	31-03-2024 (AUDITED)
I	Revenue from operations	2343.00	2657.19	1695.81	6751.00	4873.86	7072.45
II	Other income	301.03	342.99	246.60	1011.80	817.15	1231.80
III	Total Income (I + II)	2644.03	3000.18	1942.41	7762.80	5691.01	8304.25
IV	Expenses:						
	Cost of materials consumed	570.00	726.18	412.02	1794.00	1429.40	1981.13
	Purchases of Stock-in-Trade	0.00	0.00	0.00	0.00	0.00	0.00
	Changes in inventories of finished goods work-in-progress and Stock-in-Trade	-48.12	13.40	0.64	-80.49	32.92	34.27
	Employee benefits expense	145.00	180.78	122.99	455.00	373.07	514.44
	Finance costs	2.38	3.48	1.98	6.48	7.45	11.38
	Depreciation and amortization expense	22.00	22.00	20.00	66.00	60.00	86.85
	Other expenses	179.59	227.47	200.32	543.28	543.32	1031.73
	Total expenses (IV)	870.85	1173.31	757.95	2784.27	2446.16	3659.80
	Profit/(loss) before exceptional items and tax (III - IV)	1773.18	1826.87	1184.46	4978.53	3244.85	4644.45
V	Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00
VII	Profit before tax (V - VI)	1773.18	1826.87	1184.46	4978.53	3244.85	4644.45
VIII	Tax expense:						
	(1) Current tax	428.34	412.66	263.51	1146.97	729.23	1084.07
	(2) Deferred tax	0.00	0.00	0.00	0.00	0.00	139.03
IX	Profit (Loss) for the period (VII-VIII)	1344.84	1414.21	920.95	3831.56	2515.62	3421.35
X	Other Comprehensive Income/(loss)	0.00	0.00	0.00	0.00	0.00	0.00
XI	Total Comprehensive Income for the period (IX+X)	1344.84	1414.21	920.95	3831.56	2515.62	3421.35
XII	Paid-up Equity Share capital	856.84	856.84	856.79	856.84	856.79	856.84
XIII	Reserve excluding Revaluation Reserves as per balance sheet of previous year	21921.24	21921.24	16267.62	21921.24	16267.62	18860.28
XIV	Earnings per equity share:						
	(1) Basic	15.70	16.51	10.75	44.72	29.36	39.93
	(2) Diluted	15.70	16.51	10.75	44.72	29.36	39.93

PLACE : BHOPAL
DATE: 13.02.2025

FOR AND ON BEHALF OF THE BOARD


NIKHIL KUBER DUBEY
WHOLE TIME DIRECTOR
DIN:00538049



NOTES ON STANDALONE UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31st DECEMBER, 2024

1. The above results are as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended and have been taken on record by the Board of Directors at its meeting held on February 13, 2025 after being reviewed by the Audit Committee. The statutory auditors have expressed an unmodified review conclusion.
2. The Company's Agrochemical Business is seasonal in nature and the performance can be impacted by weather conditions and cropping pattern.
3. These financial results have been prepared In accordance with the requirements of Indian Accounting Standards (Ind AS) as prescribed under section 133 of Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules, 2015 as amended.
4. All the figures of financials have been rounded off to nearest lakh in rupees.
5. Previous period/Year figures have been regrouped / rearranged, wherever deemed necessary.
6. The results of the company are available for investors at www.kilpest.com and www.bseindia.com.

FOR AND ON BEHALF OF THE BOARD

NIKHIL KUBER DUBEY
WHOLE TIME DIRECTOR
DIN: 00538049

PLACE: BHOPAL
DATE: 13/02/2025



BAHETI & CO.
CHARTERED ACCOUNTANTS
24, M.P. NAGAR ZONE II
BHOPAL 462011
2763141,4251535

Limited Review Report on unaudited standalone financial results of 3B BlackBio Dx India Limited (Formerly, Kilpest India Limited) for the quarter ended 31 December 2024 and year to date results for the period from 01 April 2024 to 31 December 2024 pursuant to Regulation 33 of Securities and Exchange Board of India {Listing Obligations and Disclosure Requirements} Regulations, 2015, as amended

Review Report to
The Board of Directors of
3B BlackBio Dx Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of 3B BlackBio Dx Limited, formerly Kilpest India Limited (the "Company") for the quarter ended December 31, 2024 and year to date from April 1, 2024 to December 31, 2024 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement

For BAHETI & CO.
Chartered Accountants
(Firm Registration No 006287C)

Deepak Baheti

(DEEPAK BAHETI)
Partner



Place: Bhopal
Date: 13-02-2025

Membership No: 075063

UDIN: **25075063BMGXVX6125**

3B BLACKBIO DX LTD
(Formerly, Kilpest India Ltd.)

REGD.OFFICE: 7-C, INDUSTRIAL AREA,GOVINDPURA, BHOPAL-462 023
CIN:L24211MP1972PLC001131

Statement of Consolidated Unaudited Financial Results for the Quarter and Nine Months ended 31-12-2024

(Rs in lakhs)

S.No	PARTICULARS	QUARTER ENDED			9 MONTHS ENDED		YEAR ENDED
		31-12-2024 (unaudited)	30-09-2024 (unaudited)	31-12-2023 (unaudited)	31-12-2024 (unaudited)	31-12-2023 (unaudited)	31-03-2024 (AUDITED)
I	Revenue from operations	2539.25	2914.70	1766.89	7397.35	5112.67	7412.47
II	Other income	301.30	343.65	262.76	1014.05	833.82	1253.26
III	Total Income (I + II)	2840.55	3258.35	2029.65	8411.40	5946.49	8665.73
IV	Expenses:						
	Cost of materials consumed	615.98	751.14	497.06	1879.10	1532.87	1981.13
	Purchases of Stock-in-Trade	0.00	0.00	0.00	0.00	0.00	173.28
	Changes in inventories of finished goods work-in-progress and Stock-in-Trade	-48.12	13.40	0.64	-80.49	32.92	29.80
	Employee benefits expense	170.98	208.38	157.64	541.51	488.83	650.24
	Finance costs	2.38	3.48	2.84	6.48	8.31	12.44
	Depreciation and amortization expense	26.63	27.11	32.18	80.54	75.31	105.71
	Other expenses	293.09	324.27	224.10	838.35	747.93	1279.91
	Total expenses (IV)	1060.94	1327.78	914.46	3265.49	2886.17	4232.51
	Profit/(loss) before exceptional items and tax (III - IV)	1779.61	1930.57	1115.19	5145.91	3060.32	4433.22
V	Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00
VII	Profit before tax (V - VI)	1779.61	1930.57	1115.19	5145.91	3060.32	4433.22
VIII	Tax expense:						
	(1) Current tax	430.09	444.29	263.51	1180.35	729.23	1084.07
	(2) Deferred tax	0.00	0.00	0.00	0.00	0.00	139.03
IX	Profit (Loss) for the period (VII-VIII)	1349.52	1486.28	851.68	3965.56	2331.09	3210.12
	attributable to owners of parent	1340.34	1464.66	872.46	3925.36	2386.45	3273.49
	attributable to non-controlling interests	9.18	21.62	-20.78	40.20	-55.36	-63.37
X	Other Comprehensive Income/(loss)	0.00	0.00	0.00	0.00	0.00	0.00

[Signature]
3B BlackBio Dx Limited
BHOPAL

XI	Total Comprehensive Income for the period (IX+X)	1349.52	1486.28	851.68	3965.56	2331.09	3210.12
	attributable to owners of parent	1340.34	1464.66	872.46	3925.36	2386.45	3273.49
	attributable to non-controlling interests	9.18	21.62	-20.78	40.20	-55.36	-63.37
XII	Paid-up Equity Share capital	856.84	856.84	856.79	856.84	856.79	856.84
XIII	Reserve excluding Revaluation Reserves as per balance sheet of previous year	21690.58	21690.58	16267.62	21690.58	16267.62	18841.90
XIV	Earnings per equity share:						
	(1) Basic	15.75	17.35	9.94	46.28	27.21	37.46
	(2) Diluted	15.75	17.35	9.94	46.28	27.21	37.46

PLACE : BHOPAL
DATE: 13.02.2025

FOR AND ON BEHALF OF THE BOARD



Nikhil Kuber Dubey
NIKHIL KUBER DUBEY
WHOLE TIME DIRECTOR
DIN:00538049



NOTES ON CONSOLIDATED UN-AUDITED FINANCIAL RESULT FOR THE QUARTER AND NINE-MONTHS ENDED 31ST DECEMBER, 2024

1. The above results are as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended and have been taken on record by the Board of Directors at its meeting held on February 13, 2025 after being reviewed by the Audit Committee. The statutory auditors have expressed an unmodified review conclusion.
2. These financial results have been prepared in accordance with the requirements of Indian Accounting Standards (Ind AS) as prescribed under section 133 of Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules, 2015 as amended;
3. The Company has two identified Reportable Business Segments namely Agrochemical and Molecular Diagnostic Kits (Health Care Sector)
4. The summarized figures for M/s 3B BLACKBIO DX LIMITED (FORMERLY, KILPEST INDIA LIMITED) (Both Agrochemicals and Diagnostic Division) as a standalone entity are:

PARTICULARS	QUARTER ENDED			NINE MONTHS ENDED		YEAR ENDED
	31-12-2024	30-09-2024	31-12-2023	31-12-2024	31-12-2023	31-03-2024
	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(AUDITED)
Total Income (Rs Lakhs)	2644.03	3000.18	1942.41	7762.80	5691.01	8304.25
Profit Before Tax (Rs Lakhs)	1773.18	1826.87	1184.46	4978.53	3244.85	4644.45
Profit After Tax (Rs Lakhs)	1344.84	1414.21	920.95	3831.56	2515.62	3421.35
Basic Earnings Per Share (Rs)	15.70	16.51	10.75	44.72	29.36	39.93

5. The Consolidated Financials include the Financials of Subsidiary Company also.
6. All the figures of financials have been rounded off to nearest lakh in rupees.
7. Previous period/Year figures have been regrouped / rearranged, wherever deemed necessary.
8. The Results of the Company are available for investors at www.kilpest.com and www.bseindia.com

FOR AND ON BEHALF OF THE BOARD

PLACE: BHOPAL
DATE: 13/02/2025



NIKHIL KUBER DUBEY
WHOLE TIME DIRECTOR
DIN: 00538049



BAHETI & CO.
CHARTERED ACCOUNTANTS
24, M.P. NAGAR ZONE II
BHOPAL 462011
2763141,4251535

Limited Review Report on unaudited consolidated financial results of 3B BlackBio Dx India Limited (Formerly, Kilpest India Limited) for the quarter ended 31 December 2024 and year to date results for the period from 01 April 2024 to 31 December 2024 pursuant to Regulation 33 of Securities and Exchange Board of India {Listing Obligations and Disclosure Requirements} Regulations, 2015, as amended

Review Report
To the Board of Directors of
3B BlackBio Dx Limited

We have reviewed the accompanying Statement of unaudited consolidated financial results of 3B BlackBio Dx Limited, formerly Kilpest India Limited ('hereinafter referred to as 'the Holding Company'), its subsidiary (the Holding Company and its subsidiary together referred to as "the Group") for the quarter ended 31 December 2024 and year to date from April 1, 2024 to December 31, 2024 ('the Statement'), being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

The Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular No. CIR/CFD/CMDI/ 44/2019 dated March 29, 2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.



The Statement includes the results of the following entities:

- i. 3B BlackBio Dx Limited, Formerly Kilpest India Limited (Holding)
- ii. TRUPCR Europe Limited (Subsidiary)


Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

The unaudited interim financial results and other unaudited financial information of subsidiary has not been reviewed by their auditor and has been approved and furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the affairs of the subsidiary, is based solely on such unaudited interim financial results and other unaudited financial information. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group.

Place: Bhopal
Date: 13/02/2025

UDIN **25075063BMGXVW5483**

For BAHETI & CO.
(FRN 006287C)
Chartered Accountants



(DEEPAK BAHETI)
Partner
Membership No.075063



3B BLACKBIO DX LTD
(Formerly, Kilpest India Ltd.)

REGD.OFFICE: 7-C, INDUSTRIAL AREA, GOVINDPURA, BHOPAL-462 023

CIN:L24211MP1972PLC001131

CONSOLIDATED SEGMENTWISE

REVENUE AND RESULTS

(Rs in lakhs)

S.No	Particulars	Quarter ended 31-12-2024 Unaudited	Quarter ended 30-09-2024 Unaudited	Quarter ended 31-12-2023 Unaudited	Nine Months ended 31-12-2024 Unaudited	Nine Months ended 31-12-2023 Unaudited	Year ended 31-03-2024 Audited
1	Segment Revenue						
	(a) Agrochemicals	210.95	457.15	235.52	917.06	933.94	1368.51
	(b) Diagnostic kits	2328.30	2457.55	1531.37	6480.29	4178.73	6085.21
	Total income from operations (net)	2539.25	2914.70	1766.89	7397.35	5112.67	7453.72
2	Segment Results						
	(a) Agrochemicals	17.45	31.99	-27.77	47.06	204.54	187.47
	(b) Diagnostic kits	1764.54	1902.06	1145.81	5105.33	3088.72	4482.82
	Total Segment Profit before Interest and Tax	1781.99	1934.05	1118.04	5152.39	3293.26	4670.29
	Less : Interest Expense						
	(a) Agrochemicals	2.38	3.48	1.98	6.48	7.45	11.38
	(b) Diagnostic kits	0.00	0.00	0.86	0.00	0.86	1.07
	Profit before Tax	1779.61	1930.57	1115.20	5145.91	3284.95	4657.84
3	Segment Assets						
	(a) Agrochemicals	2810.01	2873.37	2760.67	2810.01	2760.67	2835.91
	(b) Diagnostic kits	25724.47	24383.92	21333.49	25724.47	21333.49	22365.01
	Total Segment Assets	28534.48	27257.29	24094.16	28534.48	24094.16	25200.92
4	Segment Liabilities						
	(a) Agrochemicals	371.28	446.13	330.97	371.28	330.97	427.76
	(b) Diagnostic kits	1570.81	1397.33	1071.63	1570.81	1071.63	1865.89
	Total Segment Liabilities	1942.09	1843.46	1402.60	1942.09	1402.60	2293.65
	(a) Agrochemicals	2438.73	2427.24	2429.70	2438.73	2429.70	2408.15
	(b) Diagnostic kits	24153.66	22986.59	20261.86	24153.66	20261.86	20499.12
5	Capital Employed	26592.39	25413.83	22691.56	26592.39	22691.56	22907.27

FOR AND ON BEHALF OF THE BOARD



NIKHIL KUBER DUBEY
WHOLE TIME DIRECTOR
DIN:00538049

PLACE : BHOPAL
DATE: 13.02.2025

B. STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONS PLACEMENT ETC. – Not Applicable

C. FORMAT FOR DISCLOSING OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES – Not Applicable

D. FORMAT FOR DISCLOSURE OF RELATED PARTY TRANSACTIONS (applicable only for half-yearly filings i.e., 2nd and 4th quarter) - Not Applicable

E. STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONG-WITH ANNUAL AUDITED FINANCIAL RESULTS (Standalone and Consolidated separately) (applicable only for Annual Filing i.e., 4th quarter) - Not Applicable

A handwritten signature in blue ink is written over a circular blue stamp. The stamp contains the text "SBB Bhopal D+ Limited" around the perimeter and "BHOPAL" in the center. There are two small asterisks on either side of the word "BHOPAL".